Similar to the Colon26 model, the treatment efficacy of EcN-IL-15/CR + L with anti-PD-1 was superior to that of EcN-IL-15/CR + L and anti-PD-1 administered individually, resulting in complete tumor rejection in 40% of treated mice (2/5; Figures 7D, 7E, and S20A). This evidence concerns the gene PDCD1 and neoplasm.